Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft synthesis: Human evidence for BPC-157 — submissions

The 4 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-107/2
Series
Public comment period
Version
1.0
Published
22 Apr 2025
Last reviewed
22 Apr 2025
Next review
22 Apr 2026
Identifier
10.71829/cei.cp.107
Certainty
Not rated
Cycle
2025 Q1
Window
05 Feb 2025 – 02 Apr 2025
Status
Closed
Submissions
4

§2Submissions and responses

4 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Oisín Rautavaara, PhD (Pharmacoepidemiology) Public-sector clinical trials unit · submitting on biostatistics
DRAFT-BPC-157-HUMA/001 received 07 Feb 2025

A funnel plot is presented for a set too small to interpret it

The respondent submits on the draft synthesis addressing What randomised human evidence exists for BPC-157 in any indication?. This submission concerns the methods rather than the conclusion, on the view that a conclusion is only as good as the search that produced it.

The draft includes a funnel plot for an outcome contributed by fewer than ten studies. The respondent states that asymmetry cannot be assessed reliably at that number and that presenting the plot invites a conclusion the data cannot support.

The respondent proposes that the plot be removed and replaced with a statement that publication bias could not be assessed.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted09 Apr 2025

The secretariat accepts this submission. Presenting an uninterpretable graphic is not a neutral act.

The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.

Ms Rhiannon Okoye-Vandergraaf, BSc Patient representative · submitting on patient and public involvement
DRAFT-BPC-157-HUMA/002 received 09 Feb 2025

Patient-reported outcomes are collected by the trials and not reported by the review

The respondent read the draft review of What randomised human evidence exists for BPC-157 in any indication? and has confined this submission to a single matter.

The respondent states that several contributing trials measured quality of life and function and that the review reports neither, having selected outcomes on the basis of what could be pooled.

The respondent proposes that these outcomes be reported narratively where they cannot be pooled.

Declared interest. Is a trustee of a patient organisation that has received a restricted educational grant from a manufacturer in the class under assessment.
Secretariat responseAccepted in part08 Apr 2025

The secretariat accepts this submission in part. The outcomes are reported narratively. The proposal to pool them is declined because the instruments used are not comparable and pooling would produce a figure with no interpretation.

Patient-reported outcomes measured by any contributing trial are now reported narratively by instrument, with the instrument named and its minimum important difference stated where one is published, and the absence of a pooled estimate explained.

Dr Matthias Wintringham, MD, MSc Medical affairs, marketing-authorisation holder · submitting on regulatory science · industry submission
DRAFT-BPC-157-HUMA/003 received 16 Feb 2025

A sponsor trial meeting the eligibility criteria was excluded

Having read the draft synthesis on What randomised human evidence exists for BPC-157 in any indication?, the respondent puts one point to the committee.

The submission is made on behalf of the sponsor. It identifies a completed trial of the sponsor's compound that meets the stated eligibility criteria and does not appear in the included set, and supplies the trial report and the registry record.

The sponsor asks that the trial be included and the estimate recomputed. No view is expressed on the direction the recomputation should take.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted in part22 Apr 2025

The secretariat accepts this submission in part. The trial does meet the criteria and has been included. The recomputed estimate is materially unchanged, which the response states explicitly so that the outcome of the correction is on the record.

The trial is added to the included set, the estimate and the certainty rating have been recomputed, and the screening record now states why the trial was missed, which was a database indexing gap rather than a screening judgement. The submission is identified as an industry submission.

Professor Bartolomeu Nkosi-Lindegaard, PhD Professor of Regulatory Science · submitting on regulatory science
DRAFT-BPC-157-HUMA/004 received 18 Feb 2025

Regulatory assessment documents were not searched

The respondent notes that the review question — What randomised human evidence exists for BPC-157 in any indication? — is answerable only if the contributing trials measured the same thing, and submits with that in view.

The respondent states that regulatory assessment reports frequently contain analyses that never appear in journals, and that a search limited to bibliographic databases will miss them.

The respondent proposes that regulatory documents be searched for every review in the series.

The respondent endorses the general approach taken in submission 003 and asks that it be extended to the matter identified here.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted in part08 Apr 2025

The secretariat accepts this submission in part. Regulatory assessment documents are searched. The proposal that they be treated as equivalent to a full study report is declined, because the level of detail varies and is often insufficient for risk-of-bias assessment.

Published regulatory assessment documents are now searched as a named source, are reported as a distinct evidence class in the included-studies table, and contribute to the assessment while being excluded from pooled estimates where risk of bias could not be assessed from the document.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.